• •A blood test called Hepta may predict how well patients respond to GLP-1 drugs.
• •The story is sourced from Novo Nordisk News.

Novo Nordisk's sales in India jumped 40% in April, even though generic versions of GLP-1 drugs (weight-loss and diabetes medicines) are now competing in the market. The growth shows strong demand for weight-loss drugs in India despite cheaper alternatives becoming available.

• •Novo Nordisk India sales rose 40% in April
• •Growth came despite new generic GLP-1 competition

Daewoong, a South Korean company, is developing multiple versions of a GLP-1 drug (a weight-loss medicine) including a long-acting injection, a pill, and a microneedle patch. The company is expanding its pipeline to compete in the growing obesity treatment market.

• •Daewoong is building a long-acting GLP-1 injection for obesity
• •Pipeline also includes an oral pill and a microneedle patch version
• •South Korean drugmaker pushing into the global obesity drug market

• •FDA flagged a liver failure report linked to an Eli Lilly GLP-1 drug
• •Lilly stock moved on the news

• •FDA proposal may extend Novo Nordisk GLP-1 exclusivity
• •Move could support Novo Nordisk valuation

• •Barclays says Lilly's strong GLP-1 results point to a growing market
• •Analysts see the read-across as positive for Novo Nordisk

The FDA proposed removing GLP-1 drugs from a list that allows pharmacies to make cheaper copies. Eli Lilly and Novo Nordisk stand to benefit because patients would have to buy their brand-name versions instead.

• •FDA proposed removing GLP-1 drugs from a list that lets pharmacies make copies.
• •Eli Lilly and Novo Nordisk shares rose on the news.
• •Patients would need to buy brand-name versions if the rule takes effect.

A judge threw out part of Eli Lilly's lawsuit against Empower Pharmacy, a Houston pharmacy that makes copy-cat versions of weight-loss drugs. The ruling limits what claims Eli Lilly can pursue in its case.

• •Judge dismissed part of Eli Lilly's lawsuit against Empower Pharmacy
• •Empower is a Houston pharmacy making compounded GLP-1 drugs
• •Ruling narrows the claims Lilly can pursue against the compounder

• •Novo Nordisk lowered the list price on its GLP-1 drug
• •Mercer flags follow-on questions for plan sponsors and payers

A company selling GLP-1 weight-loss drugs used fake customer reviews and had no real pharmacy, prompting an FDA warning letter. The warning signals the agency is cracking down on illegal online sellers making false claims about their products.

• •FDA sent a warning letter to a company selling GLP-1 weight-loss drugs
• •The seller used fake customer reviews to promote the drugs
• •The company had no real pharmacy behind its operation

The FDA sent a warning letter to a company that makes GLP-1 drugs after it refused to let FDA inspectors visit the factory. The agency can fine or shut down companies that won't allow inspections.

• •FDA sent a warning letter to a GLP-1 drug maker
• •The company refused to let FDA inspectors into its factory
• •FDA can fine or shut down firms that block inspections

• •Lilly and Novo shares fell on the news
• •A proposed Medicare pilot to cover GLP-1 drugs was thrown off balance

• •Hospital for Special Surgery (HSS) released studies on GLP-1 drug use around surgery